The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Hepatology International,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 27, 2025
Язык: Английский
Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence
Metabolism and Target Organ Damage,
Год журнала:
2025,
Номер
5(1)
Опубликована: Март 27, 2025
Fatty
liver
disease
associated
with
metabolic
dysfunction
has
emerged
as
a
significant
global
health
challenge.
This
condition
often
coexists
other
diseases,
such
alcohol-related
and
viral
hepatitis,
complicating
both
diagnosis
management.
To
address
the
limitations
of
non-alcoholic
fatty
(NAFLD)
classification,
two
alternative
frameworks
have
been
proposed:
dysfunction-associated
(MAFLD)
in
2020
steatotic
(MASLD)
2023.
A
key
difference
between
these
definitions
is
how
they
consider
relation
to
coexistence
conditions.
MAFLD
adopts
dual
etiology
concept,
creating
unified
classification
system
that
aligns
contemporary
clinical
epidemiological
needs.
In
contrast,
MASLD
introduces
new
term,
MetALD
(metabolic
alcohol-related/associated
disease),
describe
patients
who
excessive
alcohol
intake.
review
critically
examines
clinical,
research,
implications
differing
approaches
MASLD,
offering
insights
into
their
potential
enhance
understanding
management
multi-etiology
diseases.
Язык: Английский
MAFLD vs. MASLD: a year in review
Expert Review of Endocrinology & Metabolism,
Год журнала:
2025,
Номер
unknown, С. 1 - 12
Опубликована: Апрель 12, 2025
In
2023,
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
was
introduced
following
fatty
(MAFLD).
Both
aim
to
address
the
limitations
of
nonalcoholic
(NAFLD).
This
review
analyzes
similarities
and
differences
between
MAFLD
MASLD,
focusing
on
their
impacts
epidemiology,
diagnosis,
stigma,
related
diseases.
Current
evidence
suggests
that
criteria
effectively
identify
individuals
at
higher
risk
through
a
good
balance
sensitivity
specificity.
Moreover,
is
more
generalizable
term
easily
understood
globally.
The
transition
from
NAFLD
MASLD
marks
significant
advance
in
understanding
within
hepatology.
identifies
homogeneous
cohort
patients
with
due
dysfunction
provides
valuable
framework
for
holistic,
patient-centered
management
strategies
consider
various
contributing
factors
improve
health
outcomes.
Язык: Английский
Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
Metabolism and Target Organ Damage,
Год журнала:
2024,
Номер
4(4)
Опубликована: Ноя. 13, 2024
The
conceptual
evolution
of
non-alcoholic
fatty
liver
disease
(NAFLD)
to
what,
since
2023,
is
called
metabolic
dysfunction-associated
steatotic
(MASLD)
not
only
represents
a
change
in
the
classification
and
definition
but
also
reflects
broader
understanding
this
heterogeneous
condition,
which
still
with
many
aspects
refine.
Although
NAFLD
can
be
interchanged
high
percentage
new
MASLD
concept
different
aspects,
has
been
proposed
as
relevant
factor
that
influences
response
immunotherapeutic
treatments
management
MASLD-related
hepatocellular
carcinoma
(HCC),
compared
HCC
other
etiologies.
This
indicates
etiology
plays
role
prognosis,
highlighting
urgency
evaluating
treatment
regimens
for
subgroup
patients
upcoming
clinical
trials.
A
better
pathophysiology
generates
strategies
aid
its
provide
directly
intervene
carcinogenesis
HCC.
Язык: Английский